Airtel Money sets London IPO price at £1.96 a share
Airtel Money has priced its planned London listing at £1.96 per share, implying a market capitalisation of about £5.3 billion. Existing shareholders are expected to sell 270 million shares, with a further 27 million potentially available through an over-allotment option.
Airtel Mobile Commerce N.V., the mobile money subsidiary of Airtel Africa, has set the price for its planned initial public offering at £1.96 per share. The price implies an estimated market capitalisation of £5.3 billion, or $7 billion, when the company is admitted to trading. Airtel Africa said admission to the London Stock Exchange is currently expected on 14 October.
The offer will involve the sale of 270 million existing Airtel Money shares by certain current shareholders. A further 27 million shares could be sold if the over-allotment option is exercised in full. Airtel Africa said it does not expect to sell its existing Airtel Money shares in the offering, except through the over-allotment arrangement.
It said it would remain a long-term strategic shareholder and continue supporting the business as it becomes independently listed. Based on current indications, about 16.5% of Airtel Money’s issued ordinary share capital is expected to be held by the public if the additional shares are not sold. That proportion could rise to about 17.5% if the maximum over-allotment is exercised.
Airtel Money said the expected level of public ownership should make it eligible for inclusion in FTSE UK indices. It intends to seek admission to the equity shares category of the UK Financial Conduct Authority’s Official List and trading on the London Stock Exchange’s Main Market. Further details are due in the company’s prospectus, which Airtel Money said would be made available on its IPO website, subject to access restrictions.
The business reported $1.4 billion in turnover in 2025, more than one-third above its figure a year earlier.
This independently written report is based on information supplied by the named publisher. Vertrix News has not independently verified the source report.